Press release - 29/10/2025 Replacing, reducing and refining animal testing Official launch of integrative 3R Centre at Ulm University Developing replacement methods for animal testing is the main goal of the 3R network. One of three new 3R centres in Baden-Württemberg was launched at Ulm University at the beginning of the year and has now officially started work with a kick-off event. The abbreviation 3R stands for "Replace, Reduce, Refine", i.e. replace and reduce animal testing and improve the conditions for unavoidable animal experiments.https://www.gesundheitsindustrie-bw.de/en/article/press-release/replacing-reducing-and-refining-animal-testing-official-launch-integrative-3r-centre-ulm-university
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
rMSI technology - 08/11/2021 New multispectral imaging technology improves endoscopic tumour detection capabilities The quality of minimally invasive surgery depends to a large extent on the imaging properties of the endoscopes used. The Mannheim-based company Thericon GmbH has developed a multispectral imaging technology that overlays views from multiple light channels in real time to create a detailed image on which tumours can be better identified.https://www.gesundheitsindustrie-bw.de/en/article/news/new-multispectral-imaging-technology-improves-endoscopic-tumour-detection-capabilities
Article - 04/02/2020 Medicine from the blue blood of marine snails A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails